Evidence map›Paper›PMID 40274556›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome].

D C Dacheng, C Liang, S J Zheng

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

D C DachengThe First Department of Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
C LiangThe First Department of Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
S J ZhengThe First Department of Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Funding

Beijing Municipal Administration of Hospitals Clinical medicine Development of Special Funding Support ZYLX202125Key Research Project of Capital Health Development 2022-1-2182National Key Research and Development Program of Ministry of Science and Technology 2022YFC2304400
6 · The paper itself

Abstract

Gilbert's syndrome is a type of hereditary disease caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene, which leads to decreased UGT1A1 activity. Clinically, it is mainly characterized by increased unconjugated bilirubin and is often considered a benign disease. The incidence rate of Gilbert's syndrome is as high as 5%-10% in the population, and its interaction with commonly used clinical drugs deserves attention. On the one hand, some drugs can enhance or reduce UGT1A1 activity, causing bilirubin levels to decrease or increase. On the other hand, the decrease of UGT1A1 activity can also change part of drug metabolism, increase or reduce drug efficacy, and may cause adverse reactions and even endanger the patient's life in severe conditions. This article summarizes the interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome.

Indexed as

Gilbert DiseaseGlucuronosyltransferaseDrug InteractionsHumansUGT1A1 EnzymeGlucuronosyltransferaseUGT1A1 Enzyme

Identifiers

PMID40274556
PMCPMC12899225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.